专题：Immunodeficiency and Autoimmune Disorders

This cluster of papers focuses on the genetic basis and clinical manifestations of primary immunodeficiency disorders, including immune dysregulation, Th17 cell deficiency, common variable immunodeficiency, and defects in the interferon-? pathway. It also discusses the use of hematopoietic stem cell transplantation and immunoglobulin replacement therapy in the management of these disorders.
最新文献
Comparison of clinical characteristics in primary immunodeficiency patients based on the presence of autoimmunity or autoinflammation

article Full Text OpenAlex

Comprehensive assessment of allergic manifestations including drug hypersensitivity in adult patients with inborn errors of immunity

article Full Text OpenAlex

Fatal Systemic Granulomatous Disease Associated with Vaccine-Derived Rubella Virus in AIOLOS-Associated Immunodeficiency

article Full Text OpenAlex

Should we test routinely for autoimmunity among children with newly diagnosed type 1 diabetes mellitus?

article Full Text OpenAlex

Lymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision

article Full Text OpenAlex

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT

article Full Text OpenAlex

Immuncheckpoint-Inhibitor-assoziierte Pneumonitiden

article Full Text OpenAlex

Efgartigimod as an Add-on Therapy for Anti-IgLON5 Disease: A Case Report

article Full Text OpenAlex

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation

article Full Text OpenAlex

Severe Agranulocytosis and Thyroid Storm Triggered by Reinitiating Low-Dose Thiamazole: A Cautionary Case

article Full Text OpenAlex

近5年高被引文献
Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee

article Full Text OpenAlex 1089 FWCI90.1161

The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity

article Full Text OpenAlex 472 FWCI38.3418

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

article Full Text OpenAlex 423 FWCI59.3656

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

article Full Text OpenAlex 368 FWCI64.9966

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

article Full Text OpenAlex 278 FWCI49.5579

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

article Full Text OpenAlex 271 FWCI79.1597

Vaccination induces HIV broadly neutralizing antibody precursors in humans

article Full Text OpenAlex 247 FWCI16.7585

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

article Full Text OpenAlex 218 FWCI32.1361

Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population

article Full Text OpenAlex 213 FWCI54.6036

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

article Full Text OpenAlex 213 FWCI30.3004